Pfizer Stock Buy or Sell? PFE Stocks Analytic Forecasts

We present you the most up-to-date and complete review of analytical trend forecasts and views on the PFE stock market. Experts share their opinions on what to expect from the Pfizer Inc. stock market. How likely is the stock price to move in a bullish or bearish trend. Which should help you to make the right decision whether to Buy or Sell Pfizer stocks.

Pfizer Inc. Stock Market Experts’ Analysis and Forecasting – Sell or Buy PFE Shares?

The most recent analytical view which can help you to answer the worrying question: Should I Buy Stocks Now or Wait? came out under the authorship of Real Investments and is titled

“Pfizer: Don’t Bank On mRNA Vaccines”

is published on April 1 (2023) and has 3 likes. The review predicts Neutral market trend.

It summarize the following theses:

• A huge increase in cost may reduce demand.
• Contradictory evidence on efficacy and safety may be a concern moving forward.
• Eminent virologists cast doubt on the long-term viability of mRNA vaccines.

The author starts his analytic review with the following:

Real Investments has already 1192 followers,
which shows, he is the one who cares for his words. Real Investments has 53 works published.
The contributor of experts community since 2019

One more noteworthy article is written by ONeil Trader under the title

“What Pfizer Is Getting From The Seagen Acquisition”

on March 13 (2023) and has 4 likes. The expert reflects Neutral trend of the market.

Нis theses make you think about whether to add PFE stocks to your investment portfolio or not, and helps to work out your own Pfizer stock selling strategies:

• Pfizer will acquire Seagen for $43 billion or $229 per share.
• The deal will significantly expand Pfizer’s oncology presence and the company expects to generate more than $10 billion in risk-adjusted revenues by 2030.
• The deal also brings Pfizer a lot closer to its goal of adding $25 billion in annual revenues through business development.
• The price is somewhat higher than I expected.

ONeil Trader starts analysis with such words:

The opinion of the author can be considered quite authoritative.
The number of 7286 followers confirms this.
ONeil Trader is the contributor of experts community since 2012. Has already published at least 734 articles.

Another analysis presented by Edmund Ingham came out on March 13 (2023). Obviously, coupled with the newer reviews, this forecasting could be useful to find out the best trading strategy for PFE stocks. It sounds like

“Pfizer Buys Seagen – Why This Deal May Not Please Shareholders”

Article has got 16 likes at the moment and forecasting Neutral trend of the market.

Summarizing the information presented in the review concerning the Pfizer Inc., the expert says the following:

• Pfizer Inc. has agreed to acquire Seagen Inc. in a deal worth ~$43bn.
• Pfizer is issuing ~$31bn in long-term debt to finance the deal and paying the remainder in cash.
• Seagen is an antibody drug conjugate (“ADC”) pioneer with 4 approved drugs that earned revenues >$2bn in FY22. Guidance for 2023 is $2.3bn.
• Pfizer has had cash to burn after the resounding success of its Comirnaty COVID vaccine and COVID antiviral Paxlovid. The company has been on an M&A spree.
• This is not necessarily a deal to get shareholders excited, however. Pfizer has promised Seagen could add $10bn to its top line by 2030. There are obvious risks, however, that may outweigh benefits.

And here, what comes first:

The opinion of the author can be considered quite authoritative.
The number of 8792 followers confirms this.
Edmund Ingham is the contributor of experts community since 2018. Has already 479 analytic reviews published.